STAT+: Color Health moving deeper into cancer services, complete with virtual ‘tumor boards’

The way Color Health’s CEO Othman Laraki sees it, cancer has a scaling problem. New science regularly sets new standards of care, increasing the intricacy of managing an already complex illness. Cancer patients are multiplying faster than oncologists, Laraki said, and costs, too, are exploding. All this makes it difficult for everyone to receive the best possible therapy. The solution that the Silicon Valley executive sees is inevitable.

“In our mind, the only way this is going to be addressed and solved is in a virtual first, AI-driven manner,” Laraki said. “In the coming years, the biggest cancer centers will be virtual first.”

Virtual care for cancer may sound like an oxymoron. After all, the pillars of cancer treatment are almost all hands-on: surgery, radiation, infusions, and the like. But Color Health has been building out a virtual cancer clinic — including a virtual “tumor board” of multidisciplinary experts —  that the company says can deliver and manage care at a high quality. The company just received a certification from the American Society of Clinical Oncology to back it up.

Continue to STAT+ to read the full story…

Novelty Nobility Expands AGC Biologics Deal to Take Product Candidate Through GMP Manufacturing

Korea-based Novelty Nobility expanded its agreement with CDMO AGC Biologics to advance their bispecific antibody drug candidate through process development and GMP manufacturing at AGC Biologics’ facility in Chiba, Japan. The project leverages AGC Biologics’ global network, having completed cell line development in Copenhagen, Denmark, to be followed by tech transfer to the Chiba site for the next manufacturing stages.

“We believe this bispecific antibody has the potential to offer a truly differentiated treatment option for patients with neovascular retinal diseases,” said Sang Gyu Park, CEO of Novelty Nobility.

The product candidate, NN4101, a first-in-class, connects a fully human anti-c-Kit monoclonal antibody with a vascular endothelial growth factor (VEGF) trap.

“Our mammalian expression teams are adept at handling complex proteins, and we are a world leader in applying flexible, single-use bioreactor technology,” commented said Tadashi Murano, president of the AGC Life Science Company. “We are proud to support Novelty Nobility as they advance this innovative candidate toward the clinic.”

To further support growing demand in the region and globally, AGC is also expanding its facility in Yokohama, Japan, which is designed to utilize single-use bioreactor technology to offer large-scale GMP manufacturing.

 

The post Novelty Nobility Expands AGC Biologics Deal to Take Product Candidate Through GMP Manufacturing appeared first on GEN – Genetic Engineering and Biotechnology News.

Opinion: Dr. Glaucomflecken wants to make a stink

His real name is Will Flanary, but you probably know him as Dr. Glaucomflecken — the internet’s go-to doctor/comedian. On this episode of the “First Opinion Podcast,” we talked about how he mixes humor with some of the most pressing issues facing health care, from misinformation on social media to the corporate takeover of medicine.

In particular, Flanary has been deeply involved with advocacy around PeaceHealth’s decision to use a corporate group to staff the emergency department in Eugene, Oregon, instead of the community-based physicians who had been there for more than 35 years.

Read the rest…

Effect of pharyngeal musculature and genioglossus exercising on obstructive sleep apnea-hypopnea syndrome following uvulopalatopharyngoplasty

ObjectiveThis study aimed to evaluate the effectiveness of pharyngeal musculature and genioglossus exercising as a postoperative rehabilitation intervention for patients with obstructive sleep apnea-hypopnea syndrome (OSAHS) following uvulopalatopharyngoplasty (UPPP)—a setting with limited prior evidence.MethodsThis is a retrospective cohort study conducted in the first people’s Hospital of Linping District, Hangzhou. They included 120 patients of OSAHS who received UPPP between October 2022 and October 2024. Sixty patients who received pharyngeal and genioglossal muscle exercises were matched with the cohort who did not receive any exercise in a 1:1 ratio. The main outcome was the clinical efficacy 6 months after operation. The secondary outcomes were the changes of apnea hypopnea index (AHI), lowest oxygen saturation during sleep (LSaO2), Pittsburgh sleep quality index (PSQI), and the World Health Organisation Quality of Life tool (WHOQOL-BREF) score.ResultsSix months after operation, the clinical effective rate of the exercise group was significantly higher than that of the non-exercise group (p < 0.05). Before operation, there was no significant difference in AHI, LSaO2, PSQI and WHOQOL-BREF scores between the two groups (all p > 0.05). Six months after operation, the AHI,LSaO2, PSQI and WHOQOL-BREF scores of the two groups were significantly improved, and the AHI, LSaO2, PSQI, physical and psychological scores of the exercise group were better than those of the non-exercise group (all p < 0.05); However, there was no significant difference in the scores of environment and social domains between the two groups (all p > 0.05).ConclusionsPharyngeal musculature and genioglossus exercising may improve postoperative outcomes and quality of life in patients undergoing UPPP, and could be considered a promising rehabilitation strategy in clinical practice.

Opinion: The ‘brain drain’ narrative about health professionals misses half of the story

About 10 years after a breast surgeon we interviewed returned to Dubai to practice, a colleague stopped her in a hospital corridor to tell her: “It’s great — since you came back I no longer see those advanced cases of breast cancer.”

She had not stopped to notice. “You get on the wheel,” she told us in an interview for our research. When you return to your home country after training abroad, you run your clinics, train your nurses, drive out to women’s groups in the hinterlands to give talks, design educational videos that explain breast self-examination without showing a breast, because that is what the censors will pass. You argue to have the word “breast” printed on your medical license; the authorities prefer “chest.” You establish a support group, then a drop-in center, likely the only cancer drop-in center in the Middle East. Somewhere in the middle of all that, you alter what late-stage breast cancer looks like in your country.

Read the rest…

At-Home Sleep Electroencephalography Assessment in Young and Older Adults Using a Novel Wireless Soft Electronics Sleep Monitoring System: Experimental Study

Background: Sleep quality declines with age and is a known contributor to multiple chronic health conditions, including Alzheimer disease. Emerging evidence suggests that certain electroencephalography (EEG) neural signatures measured during sleep may be predictive of cognitive decline in older adults. Sleep EEG signals are traditionally measured using bulky, rigid, and uncomfortable equipment in an unfamiliar laboratory setting, which can negatively impact sleep signals. Due to these limitations, sleep EEG data acquisition is typically limited to a single night. Objective: This study aimed to validate our recently developed portable, skin-like EEG monitoring patch for 7 nights in the home environment in a pilot sample of young and older adults by evaluating usability and acceptance, and replicating age-related differences in sleep architecture observed in the polysomnography literature. Methods: Eighteen young adults and 18 cognitively unimpaired older adults without sleep disorders were enrolled (data from 11 young adults and 12 older adults were included in the analyses) in a 7-night study during which they wore novel, gel-free, wireless, ultrathin, skin-conforming, sleep monitoring, fabric-based patches. These patches were self-applied to the forehead and face for optimal usability and comfort. The patches incorporate laser-cut mesh electrodes with low-profile electronics (including a rechargeable battery and amplifier) and transmit EEG signals to a participant-controlled, Bluetooth-enabled, tablet-based data acquisition app. An automated algorithm was used to stage sleep and assess microarchitecture features from the EEG commonly impacted for each participant. Averages across nights were computed for these sleep features for each participant. Results: Young and older adults reported that the sleep patch was easy to use and comfortable to wear. There was no loss of signal power over 7 nights of wear across participants (retained-data signal-to-noise ratio over the 7-d period: young adult, mean 20.69, SD 12.78, maximum 52.13, minimum 5.19; older adult, mean 22.10, SD 9.39, maximum 49.96, minimum 13.79). Most datasets not retained were lost due to poor reference electrode adhesion on the nose (75/101, 74% of lost datasets in young adults and 57/88, 65% in older adults). Trained sleep technologists verified that the retained datasets were of sufficient quality to be scored without difficulty. Expected age-group differences in sleep features were observed, including age-related reductions in stage N3 sleep (young adult, mean 18.55, SD 6.70; older adult, mean 10.40, SD 6.43; Mann-Whitney =42.0; =.01) and reduced sleep spindle density (young adult, mean 2.92, SD 2.24; older adult, mean 0.94, SD 1.33; Mann-Whitney =45.0; =.006). Conclusions: This study demonstrates that our novel, comfortable, wearable patch can reliably measure physiological sleep data over multiple nights at home in adults across the lifespan, thereby making multinight sleep assessment in cognitive aging studies and clinical research more accessible than traditional polysomnography. In future studies, the small, lightweight system, which is highly scalable, can be shipped inexpensively to participants’ homes, making this technology and research accessible to individuals who may have difficulty traveling or who are hesitant to travel to a laboratory or clinic.
<img src="https://jmir-production.s3.us-east-2.amazonaws.com/thumbs/f4ea760567524def38133c78b1f4dc26" />